• HDL3-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy

    Highlights

    • Limited data are available determining the role of HDL-C sub-particles HDL2-C and HDL3-C for assessing CAD severity in patients on statin therapy.
    • This is the first study to propose HDL3-C, as a novel biomarker for predicting angiographically defined severe CAD.
    • Low HDL3-C and high Lp(a)-C levels have a significant association with Ox-LDL, a marker of inflammation.
    • In patients on statin therapy, HDL3-C and Lp(a)-C improve prediction of the presence of severe CAD compared to a traditional lipid panel.

    Abstract

    Introduction

    Low high-density lipoprotein (HDL-C) and inflammation are risk factors for coronary artery disease (CAD). However, limited data are available determining the role of HDL-C sub-particles HDL2-C and HDL3-C for assessing CAD severity in patients on statin therapy.

    Methods

    Blood samples were obtained prior to cardiac catheterization in 304 consecutive patients with suspected CAD on statin therapy in this sub-analysis of Multi-Analyte, thrombogenic, and Genetic Markers of Atherosclerosis (MAGMA, NCT01276678) study. Detailed lipid profiling and oxidized LDL (ox-LDL) were analyzed. CAD severity was angiographically defined as severe CAD (>75% luminal diameter stenosis [LDS]) and non-severe CAD (≤75% LDS). Multi-regression analysis was performed to test for statistical significance. Receiver operator curve (ROC) analysis was performed to determine cut-point for predicting severe CAD.

    Results

    Patients with severe CAD had a significantly lower total-HDL-C, lower HDL3-C and higher lipoprotein(a) levels. HDL3-C and lipoprotein(a) cholesterol [Lp(a)-C] retained statistical significance on multiple regression analysis. ROC analysis showed HDL3-C to have a C-statistic of 0.60 (p = 0.003) and Lp(a)-C to have a C-statistic of 0.61 (p = 0.0007). Patients with HDL3-C ≤ 33 mg/dL and Lp(a)-C > 7 mg/dL were found to have significantly elevated ox-LDL levels.

    Conclusion

    In patients on statin therapy, HDL3-C and Lp(a)-C improve prediction of severe CAD compared to a traditional lipid panel. In addition, patients with HDL3-C ≤ 33 mg/dL and Lp(a)-C > 7 mg/dL have greater inflammation marked by ox-LDL. Further studies are needed to evaluate the utility of these novel biomarkers in predicting CAD severity.

    Author bio

    Cardiovascular Revascularization Medicine, 2019-11-01, Volume 20, Issue 11, Pages 1001-1006, Copyright © 2018 Elsevier Inc.

    Source:

    Read the full article on Science Direct: HDL3-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details